POS1175 ANTI-IL5 THERAPY IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS: DOSAGE, EFFICACY AND OUTCOME IN A LARGE COHORT OF PATIENTS IN REAL LIFE (REVAS STUDY)

Background Eosinophilic granulomatosis with polyangiitis (EGPA), formerly Churg-Strauss syndrome, is a rare type of anti-neutrophil cytoplasm antibody-associated vasculitis, associated asthma, nasal poliposis and rinosinusitis, in which eosinophils play key role. Eosinophil targeted therapies alone or to conventional treatment corticosteroids immunosuppressant drugs may be useful patients refractory disease asthma/ENT manifestations difficult treat. Objectives To describe the indications, dosage, efficacy safety, eosinophil EGPA real practice. Methods Retrospective study evaluating all included at REVAS Registry, treated anti-IL5 therapy, order assess effectiveness safety this therapy. Treatment response was evaluated from 3 months censoring data. Complete (CR) defined as absence asthma and/or sinonasal exacerbations prednisone dosage ≤5 mg/day, partial (PR) when ≥5 mg/day. Statistical analysis performed using SSPS 21 package. Results Fifty (median age 47 years) were evaluated. Forty-five (90%) received mepolizumab (38 100 mg every 4 weeks 7 300 weeks) for mean period 31 (1-68) months; (8%) benralizumab (30 33 (7-42) months, (6%) resilizumab (n=3, 6%) 54,3 (43-67) month. Anti-Il5 therapy indicated severe steroid-dependent (94%) persistent involvement (80%). 11 (22%) also had symptoms active vasculitis (5 mononeuritis multiplex, miocarditis, 2 infiltrative cutaneous lesions, 1 orbital pseudotumor). ANCA positive 27 (54%) cases MPO specificity. All receiving time beginning, 11,5 A total previously omalizumab, that changed 9 cases, reslizumab another, due PR (n=5) recurrence sinusitis (n=6) after long (70.5 months). Anti-IL5 given concomitantly AZA MTX 3, RTX 2. 38 (84,4%) achieved CR 6-18 treatment. The median 6 mepolizumab, initiation (5-15) 5.3 (2.5-10) 3.3 (0-5) respectively. 12 beginning 3.5 3.1 mg/day 2.5 number decreased over previous following months. CS stopped (24%) patients. safe well tolerated. During follow-up period, three experienced major relapse disease, successfully conjunction no serious adverse events. Mepolizumab reduced 50% cases. In one case by PR. Conclusion both effective EGPA. Both doses should compared setting controlled trial. Benralizumab are effective. Sequential rituximab achieving remission disease. REFERENCES: NIL. Acknowledgements: Disclosure Interests None Declared.